If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more: https://t.co/3fayvkMReI
If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more: https://t.co/3fayvkMReI
This clinical research study is evaluating an investigational treatment option to potentially help manage and slow the progression of immunoglobulin A nephropathy (IgAN), or Berger’s disease. Learn more: https://t.co/3fayvkMReI
Patients living with Immunoglobulin A nephropathy (IgAN), or Berger’s disease, may be eligible for a clinical research study that may help improve kidney function and slow the progression of IgAN. Learn more: https://t.co/lmIArrao9n
Join us virtually as we highlight real-world implementation data from NKF’s flagship CKDintercept program, a national strategy to improve CKD testing, diagnosis, and management in the primary care setting. RSVP: https://t.co/59uI1nTNyS
Today is #C3GAwarenessDay! C3G is a rare kidney disease with a lifelong impact. Explore our resources for understanding, diagnosing, and treating C3G. https://t.co/xj5hm26RjC
Patients with kidney disease deserve more than outdated technology and limited options. Let’s create better treatments and better outcomes. https://t.co/WcxCLd2EdZ
We are one community united by a shared belief in the lifesaving power of our collective steps. Will you contribute to our goal by walking with us? https://t.co/Mh7WWVP0Fg #KidneyWalk
Jessika and Joey didn’t let kidney failure stop them from falling in love or planning a wedding at the Kidney Walk. Here’s how their NKF community helped make it happen. https://t.co/z9pxingY5a
TODAY is Kidney Heroes Giving Day!
Today we honor KIDNEY HEROES and the life-changing difference they make for people with kidney disease. From donors and recipients to doctors and family members, anyone can be a kidney hero.
Honor your hero: https://t.co/8HU4q48Ii9
When Patrick experienced sudden foot pain, he never imagined it would lead to a diagnosis of IgA nephropathy, or IgAN, a serious form of chronic kidney disease. https://t.co/xjsCEdtiNM
If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more: https://t.co/lmIArrao9n
Tell your legislator to support programs that work to increase early detection, improve outcomes, address health disparities, and develop innovative treatments for kidney patients. https://t.co/bMTt90Y5gQ
This clinical research study is evaluating an investigational treatment option to potentially help manage and slow the progression of immunoglobulin A nephropathy (IgAN), or Berger’s disease. Learn more: https://t.co/lmIArrao9n
RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational cell therapy, CABA-201, in patients with active lupus nephritis (LN) or active lupus (SLE) without renal involvement.
Learn more about the study at https://t.co/USs66KtCm0.
Today is #FSGS Awareness Day! The New Era Act helps patients with rare kidney diseases by promoting early detection of rare and genetic kidney diseases, enhancing education of doctors and patients, and conducting more research. We need YOUR voice to push it across the finish line. https://t.co/PhwuQlp9Q9
Patients living with Immunoglobulin A nephropathy (IgAN), or Berger’s disease, may be eligible for a clinical research study that may help improve kidney function and slow the progression of IgAN. Learn more: https://t.co/lmIArrao9n